- Home
- NRO vs ADCT Comparison
NRO vs ADCT Comparison
Compare NRO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRO
- ADCT
- Stock Information
- Founded
- NRO 2003
- ADCT 2011
- Country
- NRO United States
- ADCT Switzerland
- Employees
- NRO N/A
- ADCT N/A
- Industry
- NRO Finance/Investors Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- NRO Finance
- ADCT Health Care
- Exchange
- NRO Nasdaq
- ADCT Nasdaq
- Market Cap
- NRO 160.6M
- ADCT 143.1M
- IPO Year
- NRO N/A
- ADCT 2020
- Fundamental
- Price
- NRO $3.35
- ADCT $1.63
- Analyst Decision
- NRO
- ADCT Strong Buy
- Analyst Count
- NRO 0
- ADCT 5
- Target Price
- NRO N/A
- ADCT $8.00
- AVG Volume (30 Days)
- NRO 239.4K
- ADCT 493.2K
- Earning Date
- NRO 01-01-0001
- ADCT 03-12-2025
- Dividend Yield
- NRO 11.41%
- ADCT N/A
- EPS Growth
- NRO N/A
- ADCT N/A
- EPS
- NRO N/A
- ADCT N/A
- Revenue
- NRO N/A
- ADCT $70,717,000.00
- Revenue This Year
- NRO N/A
- ADCT $6.81
- Revenue Next Year
- NRO N/A
- ADCT $11.23
- P/E Ratio
- NRO N/A
- ADCT N/A
- Revenue Growth
- NRO N/A
- ADCT N/A
- 52 Week Low
- NRO $2.51
- ADCT $1.39
- 52 Week High
- NRO $3.45
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- NRO 45.59
- ADCT 46.49
- Support Level
- NRO $3.32
- ADCT $1.55
- Resistance Level
- NRO $3.37
- ADCT $1.73
- Average True Range (ATR)
- NRO 0.06
- ADCT 0.12
- MACD
- NRO 0.01
- ADCT 0.03
- Stochastic Oscillator
- NRO 52.63
- ADCT 63.16
About NRO Neuberger Berman Real Estate Securities Income Fund Inc.
NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND INC is a closed-end management investment company that invests mainly in securities issued by real estate companies, including real estate investment trusts (REITs). Its primary objective is to gain high current income with capital appreciation being the second. Under normal market conditions, the Fund invests at least 90% of its total assets in income-producing common equity securities, preferred securities, convertible securities and non-convertible debt securities issued by real estate companies, including real estate investment trusts ("REITs").
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.